Cue Biopharma released updated data from the Phase I clinical trial of cue-101 for recurrent/ metastatic HPV-positive head and neck cancer at the 2024 ASCO Annual Meeting.
cue biopharma在2024年asco年会上发布了cue-101用于复发/转移HPV阳性头颈癌的一期临床试验的更新数据。
Cue Biopharma released updated data from the Phase I clinical trial of cue-101 for recurrent/ metastatic HPV-positive head and neck cancer at the 2024 ASCO Annual Meeting.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.